X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DIVIS LABORATORIES ASTRAZENECA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 141.9 31.9 445.0% View Chart
P/BV x 21.5 5.2 416.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ASTRAZENECA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
ASTRAZENECA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2851,222 105.2%   
Low Rs634784 80.9%   
Sales per share (Unadj.) Rs189.6153.1 123.8%  
Earnings per share (Unadj.) Rs-0.239.9 -0.5%  
Cash flow per share (Unadj.) Rs3.844.6 8.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs68.6201.8 34.0%  
Shares outstanding (eoy) m25.00265.47 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.16.6 77.3%   
Avg P/E ratio x-4,712.725.1 -18,768.5%  
P/CF ratio (eoy) x249.622.5 1,109.6%  
Price / Book Value ratio x14.05.0 281.3%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m23,988266,266 9.0%   
No. of employees `0001.69.7 16.0%   
Total wages/salary Rs m1,6054,687 34.2%   
Avg. sales/employee Rs Th3,040.24,175.0 72.8%   
Avg. wages/employee Rs Th1,029.2481.5 213.8%   
Avg. net profit/employee Rs Th-3.31,089.3 -0.3%   
INCOME DATA
Net Sales Rs m4,74040,643 11.7%  
Other income Rs m92749 12.3%   
Total revenues Rs m4,83241,392 11.7%   
Gross profit Rs m-13014,460 -0.9%  
Depreciation Rs m1011,233 8.2%   
Interest Rs m023 0.0%   
Profit before tax Rs m-13913,953 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m53,349 0.2%   
Profit after tax Rs m-510,604 -0.0%  
Gross profit margin %-2.735.6 -7.7%  
Effective tax rate %-3.724.0 -15.3%   
Net profit margin %-0.126.1 -0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72640,105 6.8%   
Current liabilities Rs m2,4356,595 36.9%   
Net working cap to sales %6.182.5 7.5%  
Current ratio x1.16.1 18.4%  
Inventory Days Days74119 62.2%  
Debtors Days Days4181 50.5%  
Net fixed assets Rs m1,03519,995 5.2%   
Share capital Rs m50531 9.4%   
"Free" reserves Rs m94253,043 1.8%   
Net worth Rs m1,71653,574 3.2%   
Long term debt Rs m00-   
Total assets Rs m4,15661,585 6.7%  
Interest coverage xNM618.4-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.7 172.8%   
Return on assets %-0.117.3 -0.7%  
Return on equity %-0.319.8 -1.5%  
Return on capital %026.1 0.0%  
Exports to sales %5.70-   
Imports to sales %6.525.2 25.6%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m30610,259 3.0%   
Fx inflow Rs m37535,384 1.1%   
Fx outflow Rs m47010,399 4.5%   
Net fx Rs m-9624,985 -0.4%   
CASH FLOW
From Operations Rs m-811,493 -0.1%  
From Investments Rs m-146-11,372 1.3%  
From Financial Activity Rs m862-93 -926.1%  
Net Cashflow Rs m70928 2,494.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 15.7 19.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   12,856 31,796 40.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS